RazorMetrics has launched an AI-driven Polypharmacy Solution aimed at reducing medication overload affecting nearly a quarter of U.S. adults, optimizing patient safety and lowering healthcare costs.

Illumina and NVIDIA have announced a groundbreaking collaboration to advance multiomic data analysis, promising to accelerate drug discovery and precision health. By integrating Illumina’s sequencing technologies with NVIDIA’s AI tools, the partnership aims to revolutionize the analysis and interpretation of genomic data.

A new study reveals that Kognitic’s AI neural network model dramatically improves the accuracy of clinical trial completion predictions, reducing errors from 508 to 179 days. This advancement promises significant cost savings for pharmaceutical companies facing costly delays.

Shares of Moderna tumbled sharply on Monday after the vaccine maker projected a larger-than-anticipated drop in sales for 2025. The unexpected forecast surprised analysts and investors, signaling potential challenges ahead for the biotech firm.

Applied Therapeutics is under fire as investors file a class action lawsuit following the FDA’s refusal to approve its lead drug, causing stock prices to plummet over 80%. Investors have until February 18, 2025, to join the lawsuit alleging securities fraud.

Kyverna Therapeutics faces a class action lawsuit alleging the company made false statements and concealed critical information during its February 2024 IPO. Investors who purchased stock may be eligible to join the lawsuit led by Levi & Korsinsky, LLP.

Investors in Humacyte, Inc. have filed a class action lawsuit alleging securities fraud against the company. The suit claims that Humacyte concealed critical manufacturing deficiencies, leading to investor losses. Affected shareholders have until January 17, 2025, to seek lead plaintiff status.

Investors in Dentsply Sirona Inc. are being notified of a class action lawsuit alleging securities fraud related to the company’s Byte aligners. The lawsuit claims that Dentsply concealed severe patient injuries and failed to report them to the FDA, potentially misleading investors about the company’s financial health.

Cassava Sciences is facing a class-action lawsuit following the failure of its Alzheimer’s drug candidate, simufilam, in Phase 3 trials. Investors allege securities fraud after the company’s stock plummeted by over 80% in a single day.

Biotech firm Immunic, Inc. announced significant progress in developing treatments for multiple sclerosis, with upcoming trial results and strengthened leadership bolstering their efforts. The company’s lead drug, vidofludimus calcium, shows promise in both relapsing and progressive forms of the disease.

The global smart mining market is projected to exceed $40.5 billion by 2032, driven by the integration of advanced technologies that enhance operational efficiency and safety. Environmental regulations and investments in tech startups are accelerating the adoption of smart solutions in the mining industry.

At CES 2025, Samsung announced that Ballie, its AI-powered rolling robot, will be available to consumers in the first half of the year. With voice recognition and projection capabilities, Ballie aims to redefine the smart home experience.

Zomedica Corp. has announced an exclusive agreement to market Cresilon’s revolutionary Vetigel® hemostatic gel in the U.S., marking a significant expansion of its veterinary health portfolio.

Liam Kelly, Chairman, President, and CEO of Teleflex Incorporated, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will be available via live audio webcast on the Teleflex investor website, offering insights into the company’s mission to improve global health.

SpringWorks Therapeutics’ CEO, Saqib Islam, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The announcement follows the company’s recent FDA approval of their first therapy, OGSIVEO®, marking a significant milestone in their mission to treat severe rare diseases and cancer.

As Chinese-made drones dominate U.S. skies, Congress moves to halt new sales, citing espionage fears and a struggling domestic industry. This legislative push reflects the growing technological rivalry between the United States and China.

Despite advanced software, harmful medication errors persist with current infusion pumps. The innovative Ivenix system aims to change that by enhancing drug delivery efficiency and patient safety.